1. Compared with the GnRH agonist drug class, which one of the following describes the GnRH antagonist drug class?

2. Which one of the following is an important role of specialty pharmacy services in the multidisciplinary care of men with prostate cancer?

3. A 68-year-old man, Samuel, is diagnosed metastatic castrate-sensitive prostate cancer (mCSPC). His medical history is notable for type 2 diabetes, which is controlled with diet and metformin, and hypercholesterolemia, which is controlled with moderate-dose statins. He is initiated on ADT plus enzalutamide. Six months after starting therapy, he presents for follow-up and has blood pressure of 145/98 mm Hg, which is up from his baseline of 118/75 mm Hg. Which one of the following is the appropriate next step?

4. Which of the following contributes to the elevated risk of prostate cancer mortality among Black men?

5. A 65-year-old man, Joseph, was diagnosed with intermediate-risk prostate cancer 5 years ago. He underwent radiation therapy with 2 years of ADT. Over the last year, he has had biochemical recurrence. At his most recent follow-up visit, his PSA levels were 28 ng/mL with a PSA doubling time of 12 months. He is initiated on leuprolide acetate. One month later, he presents to the clinic and his testosterone levels have increased to 550 ng/dL with leuprolide treatment. Which one of the following is the best next step?

6. A 71-year-old man is diagnosed with mCSPC. He has a history of uncontrolled hypertension and hypercholesterolemia. Which one of the following treatments would you recommend as first-line therapy in addition to ADT?

7. Which one of the following ADT agents can be administered orally?

8. Which one of the following antiandrogen therapies should be administered on an empty stomach?

9. According to the most recently available data, what proportion of prostate cancer clinical trial participants are Black men?

10. Which one of the following agents is least likely to cause tumor flare?

« Return to Activity